June Edition: Parkinson’s disease and the rate of ALS progression - a podcast by BMJ Group

In this podcast, Elizabeth Highton investigates the details of two studies selected for the June 2016 edition of JNNP.

Professor Steve Vucic, from the Department of Neurology at Westmead Hospital, Sydney, talks about the details of his study, which concludes that the rate of ALS progression appears to be a simple and sensitive clinical prognostic biomarker in the disease that could be potentially utilised in clinical practice and future therapeutic trials.The paper “Rate of Disease Progression: A Prognostic Biomarker in ALS”, which was selected as Patient choice this month, can be read here: http://jnnp.bmj.com/content/87/6/628.full .

Dr Helen Ling, Senior Research Associate at UCL Institute of Neurology in London, explains the correlations of the diagnosis of Parkinson’s disease with the phenomenon of SWEDD.

Read the full study selected for Editor’s Choice, “Parkinson’s disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?” here: http://jnnp.bmj.com/content/87/6/633.full.

Further episodes of JNNP podcast

Further podcasts by BMJ Group

Website of BMJ Group